home
顺序
主题
题目
日子
131
FDA Approval Sought for Frontline Camrelizumab Plus Rivoceranib in uHCC
admin
2023.05.23
130
Elevar submits new drug application for uHCC combo therapy
admin
2023.05.23
129
HLB seeks approval for liver cancer drug with US FDA
admin
2023.05.23
128
HLB ends split-off of ship business to focus on bio sector
admin
2023.04.21
127
HLB Cell produces extracellular matrix Hutrigel
admin
2023.04.06
126
HLB's US subsidiary promotes efficacy of liver cancer drug Rivoceranib
admin
2023.03.27
125
PSMC emerges as core of HLB Group interested in CAR-T drugs
admin
2023.03.07
124
HLB's anticancer drug receives greenlight in China
admin
2023.02.02
123
HLB set to apply for conditional domestic approval of rivoceranib
admin
2022.11.09
122
HLB completes preparatory meeting with FDA for approval of liver cancer drug
admin
2022.10.14